Long-term effects of automated mechanical peripheral stimulation on gait patterns of patients with Parkinson&apos;s disease by Stocchi, Fabrizio et al.
Original Citation:
Long-term effects of automated mechanical peripheral stimulation on gait patterns of patients with
Parkinson's disease
Lippincott Williams and Wilkins
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3209311 since: 2016-11-15T13:23:22Z
10.1097/MRR.0000000000000120
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
Long-term effects of automated mechanical peripheral
stimulation on gait patterns of patients with Parkinson’s
disease
Fabrizio Stocchia, Patrizio Salea, Ana F.R. Kleinerb,c, Miriam Casalia,
Veronica Cimolind, Francesca de Pandisc, Giorgio Albertinia
and Manuela Gallia,b
New treatments based on peripheral stimulation of the
sensory–motor system have been inspiring new
rehabilitation approaches in Parkinson’s disease (PD),
especially to reduce gait impairment, levodopa washout
effects, and the incidence of falls. The aim of this study was
to evaluate the change in gait and the clinical status of PD
patients after six sessions of a treatment based on
automated mechanical peripheral stimulation (AMPS).
Eighteen patients with PD and 15 age-matched healthy
individuals (control group) participated in this study. A
dedicated medical device delivered the AMPS. PD patients
were treated with AMPS six times once every 4 days. All PD
patients were treated in the off-levodopa phase and were
evaluated with gait analysis before and after the first
intervention (acute phase), after the sixth intervention, 48 h
after the sixth intervention, and 10 days after the end of the
treatment. To compare the differences among the AMPS
interventions (pre, 6 AMPS, and 10 days) in terms of clinical
scales, a t-test was used (α≤ 0.05). In addition, to compare
the differences among the AMPS interventions (pre, post,
6 AMPS, 48 h and 10 days), the gait spatiotemporal
parameters were analyzed using the Friedman test and the
Bonferroni post-hoc test (α≤0.05). Also, for comparisons
between the PD group and the control group, the gait
spatiotemporal parameters were analyzed using the
Mann–Whitney test and the Bonferroni post-hoc test
(α≤ 0.05). The results of the study indicate that the AMPS
treatment has a positive effect on bradykinesia because it
improves walking velocity, has a positive effect on the step
and stride length, and has a positive effect on walking
stability, measured by the increase in stride length. These
results are consistent with the improvements measured
with clinical scales. These findings indicate that AMPS
treatment seems to generate a more stable walking pattern
in PD patients, reducing the well-known gait impairment
that is typical of PD; regular repetition every 4 days of AMPS
treatment appears to be able to improve gait parameters, to
restore rhythmicity, and to reduce the risk of falls, with
benefits maintained up to 10 days after the last treatment.
The trial was registered online at ClinicalTrials.gov (number
identifier: NCT0181528). International Journal of
Rehabilitation Research 38:238–245 Copyright © 2015
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Impairment of the motor system (basal ganglia and motor
cortex) is traditionally considered the major cause of
Parkinsonian symptoms. Individuals with Parkinson’s
disease (PD) have been reported to have deficits in both
sensorimotor integration (Fuhrer et al., 2014) and per-
ipheral sensory function (Pratorius et al., 2003). Although
these sensory system impairments are believed to result
in poor feedback to the motor system, thereby producing
observable motor deficits, whether these deficits are
because of reduced peripheral sensory receptor function
or impaired central sensorimotor integration is unknown
(Lewis and Byblow, 2002). Treatments based on auto-
mated mechanical peripheral stimulation (AMPS) of the
sensory–motor system (bottom-up stimulation) have
been inspiring new rehabilitation approaches in PD
(Jenkins et al., 2009).
Different methods of plantar sensory stimulation have been
studied, including insoles with a raised ridge located at the
foot’s perimeter (Maki et al., 2007; Perry et al., 2008),
mechanical pressure on the sole of the foot (Maurer et al.,
2001), and vibratory insoles (Priplata et al., 2003; Novak and
Novak, 2006). Duysens et al. (2008) found that vibration to
the soles of the feet elicited stretch reflexes. Mechanical
facilitation, by way of vibration, could induce a response
from the proprioceptors, which can in turn affect the gait of
an individual. This is reasonable as various types of sensory
receptors work together to provide accurate feedback to the
central nervous system during locomotion.
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Jenkins et al. (2009) evaluated the effects of a facilitatory
insole that provided increased plantar sensory stimulation
to PD patients during gait. The results indicated that the
use of the facilitatory insole induced a significant increase
in single-limb support time. In addition, the muscle
activation sequence of the tibialis anterior was normal-
ized by the facilitatory insole at the point of initial ground
contact. Thus, mechanical facilitation of the plantar sur-
face may be able to increase the sensory stimulation
received to overcome the proprioceptive deficits that
impair gait in individuals with PD.
In a recent study by Barbic et al. (2014), the effects of a
manual mechanical peripheral stimulation (manual MPS)
in PD patients have been studied. The treatment
investigated in that study consisted of the application of a
punctual pressure in a range of 0.3–0.9 N/mm2 in a
sequence of four specific foot points. The authors eval-
uated a group of 16 patients with PD preacute phase and
postacute phase (‘post’ meaning immediately after one
manual AMPS treatment only). The authors measured
significant improvements in step length and gait velocity,
showing that manual MPS could be an encouraging
treatment to reduce motor impairment in PD patients.
The manual MPS treatment used in that study, however,
may be operator dependent, resulting a nonhomogenous
application of the treatment to all participants. In addi-
tion, the manual treatment can be provided only in a
clinical environment, not in a domestic scenario.
Tomake the application of theMPS treatment available in an
automated way, a new non-operator-dependent medical
device (Gondola; Ecker Technologies, Lugano, Switzerland)
has been developed. The aim of the present study is to verify
the effect of the AMPS treatment for the rehabilitation of gait
and for the functionality of patients with PD. More specifi-
cally, the current study aims to evaluate the effect of the
AMPS treatment by analyzing both clinical scales and gait
analysis tests to measure gait spatiotemporal parameters at the
following time points: basal condition (pretreatment), after a
cycle of six treatments, and 48 h and 10 days after the end of a
3-week treatment cycle.
The hypothesis of this study is that the AMPS stimulation
improves the gait of patients with PD as well their clinical
status, that these improvements exert positive effects on
motor capabilities, and that these improvements are main-
tained up to 10 days after a treatment cycle.
Methods
The study was approved by the Ethics Research
Committee of the IRCCS San Raffaele Institute and
written informed consent was obtained by the patients.
The investigation was registered online at ClinicalTrials.
gov (number identifier: NCT0181528). All procedures
were explained and performed with an adequate
understanding and written informed consent of the
participants.
Participants
We studied 18 patients with idiopathic PD (age:
67.58 ± 8.74 years; height: 1.60 ± 0.10 m; weight:
73.77 ± 14.13 kg). The group was characterized by a
moderate motor impairment (Hoehn and Yahr, 1967,
scale 2–3) and had been referred to the outpatient clinic
of the Parkinson’s Disease Center. Each case of PD was
diagnosed on the basis of clinical criteria (Nutt and
Wooten, 2005), a dopamine transporter scan, and/or MRI.
Patients were homogeneous in terms of disease duration
and were free of peripheral sensory neuropathy and/or
other disorders on the basis of their reported history,
symptoms, physical examination, and routine tests.
Patients with liver, kidney, lung, heart disease, diabetes,
or other causes of autonomic dysfunction were not
included in the study. Treatments for PD remained
unchanged for the 30 days preceding the study. A clinical
team comprising a neurologist and a physical therapist
examined all participants. They were assessed by clinical
evaluation and gait analysis before and after AMPS
treatment.
A control group of 15 healthy individuals (age: 68.11 ±
8.70 years; height: 1.56 ± 0.09 m; weight: 72.66 ± 15.50 kg)
was used as a normality group for gait analysis. This group
was included in the study to define a reference set of data
of age-matched healthy participants and to compare data
of the patient group with the data of the control group.
Exclusion criteria for the healthy participants included a
previous history of cardiovascular, neurological, or mus-
culoskeletal disorders. They showed normal flexibility
and muscle strength and no obvious gait abnormalities.
Definitions and AMPS procedures
A dedicated medical device (Gondola; Ecker Technologies,
Lugano, Switzerland) was used to deliver the AMPS
(Fig. 1a). The system consists of feet supports (left and
right) with electrical motors that activate two actuated steel
bars with a diameter of 2mm (Fig. 1b); the motor-activated
stimulators apply a mechanical pressure in two specific areas
for each foot (Fig. 1c): on the head of the hallux, left and
right, and on the first metatarsal joint, left and right.
Before treatment, the device needs to be adjusted to the
patient’s feet: a plantar of the correct size is mounted on
each unit (left and right) to accommodate the feet; the
feet are inserted in the two units and tied using three
straps per foot; and then steel bars of the correct length
are mounted on the axis of the electrical motors. The
next step consists of positioning the motors – which are
mounted on adjustable platforms – in order to make the
steel bars interact with the areas to be stimulated (head of
the hallux and first metatarsal joint of both feet). When
the device has been adjusted, the excursion of the four
motors (independently for each one) is programmed with
a remote control to apply the correct pressure stimulation
in each area. The pressure of stimulation – always applied
in a range of 0.3–0.9 N/mm2 – is set for each participant
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upon appearance of the monosynaptic reflex in the
tibialis anterior muscle by the detection of a liminaris
contraction while applying pressure in the contact areas.
Once the pressure value has been set using this proce-
dure, the value is recorded to administer the AMPS. This
preparatory procedure requires ∼ 10 min.
The treatment consists of four cycles; one cycle included
a stimulation of the four target areas requiring 24 s,
whereas the overall treatment included four cycles lasting
a total of 96 s. During the AMPS treatment, patients lay
down (Fig. 1d).
At the end of the AMPS stimulation, both units of the
device are removed from the feet of the patient; this final
action is very easy and fast (less than 1 min).
During the current study, every patient underwent two
AMPS sessions per week for 3 weeks (total: 6 AMPS
sessions/patient).
Intervention
PD patients were treated with the AMPS six times at four
intervals. All patients with PD were in a defined off-
phase.
All patients with PD were evaluated by gait analysis
before and after the first intervention (‘acute’ phase),
after six interventions, 48 h after the sixth intervention,
and 10 days after the end of the treatment cycle. The
clinical tests were applied before the treatment (pre),
at the end of the treatment (after the cycle of 6 AMPS
sessions), and 10 days after the end of the treat-
ment cycle.
Clinical evaluations
The patients in the PD group were assessed using the
following clinical scales:
(1) Unified Parkinson’s Disease Rating Scale III
(UPDRS III): UPDRS is a rating scale used to follow
the longitudinal course of PD; section III refers to
clinically scored motor evaluation. It has ratings
ranging from 0 to 4, in which the severity of the
symptoms is rated 0 (normal) to 4 (severe) (Goetz
et al., 2008).
(2) Functional ambulation classification: categorization
patients according to the basic motor skills necessary
for functional ambulation, from 1 (nonfunctional) to 6
(independent) (Holden et al., 1984);
(3) Parkinson’s Disease Questionnaire (PDQ39): a self-
completion questionnaire designed to address aspects
of functioning and well-being for patients affected by
PD. Patients are asked to think about their health
Fig. 1
(a) The Gondola device; (b) two moving steels; (c) points of stimulation on the feet; (d) patient positioning.
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and general well-being and to consider how often in
the last month they have experienced certain events
(e.g. difficulty walking 100 yards) and to indicate the
frequency of each event by selecting one of 5
options, ranging from 0 (never) to 4 (always) (Peto
et al., 1998).
(4) Tinetti Assessment Tool: a simple, easily adminis-
tered test that measures a patient’s gait and balance.
The test is scored on the patient’s ability to perform
specific tasks. Scoring of the Tinetti Assessment
Tool is calculated on a three-point ordinal scale with
a range of 0 (the most impairment) to 2 (indepen-
dence). The individual scores are then combined to
form three measures: an overall gait assessment score,
an overall balance assessment score, and a gait and
balance score. The maximum score for the gait
component is 12 points. The maximum score for the
balance component is 16 points. The maximum total
score is 28 points. In general, patients who score
below 19 are at a high risk for falls. Patients who score
in the range of 19 to 24 indicate that the patient has a
risk for falls (Tinetti, 1986).
(5) 10 Meters Walk Test (10MWT): assesses walking
speed in meters per second over a short duration.
Older adults should walk between 0.9 and 1.3 m/s
(Bohannon, 1997).
(6) Timed Up and Go (TUG): assesses the time that an
individual takes to rise from a chair, walk 3 m, turn
around, walk back to the chair, and sit down. One
source suggests that scores of 10 s or less indicate
normal mobility, 11–20 s are within normal limits for
frail elderly and disabled patients, and greater than
20 s means that the individual needs assistance
outside and indicates further examination and inter-
vention. A score of 14 s or more suggests that the
individual may be prone to falls (Bischoff et al., 2003;
Podsiadlo and Richardson, 1991).
Experimental procedures for gait analysis
All participants were assessed for gait analysis using an
optoelectronic system (BTS, Milan, Italy) with passive
markers positioned according to the Davis marker-set
(Davis et al., 1991) and a synchronic video system (BTS).
After the collection of some anthropometric measures
(height, weight, tibial length, distance between the
femoral condyles or diameter of the knee, distance
between the malleoli or diameter of the ankle, distance
between the anterior iliac spines, and thickness of the
pelvis), passive markers were placed at special points of
reference, directly on the patient’s skin, as described by
Davis et al. (1991) to evaluate the kinematics of each
body segment. In particular, they were placed at C7,
sacrum and bilaterally at the anterior superior iliac spine,
greater trochanter, femoral epicondyle, femoral wand,
tibial head, tibial wand, lateral malleolus, lateral aspect of
the foot at the fifth metatarsal head, and at the heel (only
for static offset measurements). To assure the reprodu-
cibility of the aquisition technique and to avoid the errors
due to different operators the same health professional
made all aquisitions. The participant was asked to walk
barefoot at a self-selected speed along a 10 m flat walk-
way. A minimum of seven trials were acquired for each
session to ensure repeatability of the measure. At least
four steps for each trial were acquired and among these,
two subsequent strides (one for the right side and one for
the left side) were considered for each trial; the selected
strides are those in the center of the lab so that the par-
ticipant is assessed at the steady-state walking condition.
All data obtained from gait analysis were normalized as %
of the gait cycle. Although kinematics (angles of the main
lower limbs) were also acquired during this study, these
are not included in the present analysis and are not dis-
cussed in this paper. In the present study, only spatio-
temporal gait variables were analyzed.
Dependent variables
The following parameters were considered.
(1) Mean velocity (m/s): mean velocity of progression,
computed as the average instantaneous speed of the
marker placed on sacrum.
(2) Swing velocity (m/s): velocity of each leg during the
swing phase according to the ratio between the
distance covered during the limb swing phase and
the time of the swing phase.
(3) Cadence (steps/min): number of steps in a time unit.
(4) Stride length (m): longitudinal distance between
successive points of heel contact of the same foot.
(5) Step length (m): longitudinal distance from one foot
strike to the next one.
(6) Step width (m): mediolateral distance between the
two feet during double support.
(7) Stance phase (as % of the gait cycle): percentage of
the gait cycle when both feet are on the ground.
(8) Swing phase (as % of the gait cycle): percentage of
the gait cycle when foot swings forward between one
episode of ground contact and the next.
(9) Double support (as % of the gait cycle): the duration
of the phase of support on both feet as percentage of
gait cycle.
Statistical analysis
For the statistical analysis, an analysis of variance one-
way (α≤ 0.05) was first used for the comparison for
anthropometric data (age, body mass, and height)
between the PD and the control groups.
For the statistical analysis, the data normality was tested
using the Kolmogorov–Smirnov test. Then, t-tests were
used to compare the differences among AMPS interven-
tions (pre, 6 AMPS, and 10 days after the last treatment)
and clinical scales. To compare the differences among the
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AMPS interventions (pre, post, 6 AMPS, 48 h, and
10 days) for the gait spatiotemporal parameters, the non-
parametric data were analyzed using the Friedman test
and Bonferroni post-hoc test (α≤ 0.05). Finally, the
Mann–Whitney test and the Bonferroni post-hoc test
(α≤ 0.05) were used to compare the gait spatiotemporal
parameters of the PD group versus the control group. The
SPSS software (version 19 IBMCorp, Armonk, New York,
USA) was used to carry out all statistical analyses.
Results
A one-way analysis of variance showed no significant
differences between the patients with Parkinson’s and
the control group in terms of age (P= 0.883), body mass
(P= 0.291), or height (P= 0.853).
Clinical scales results
Below, the results of the evaluation of clinical scales are
reported as described in the material and methods sec-
tion, applied before the treatment, after the last (sixth)
stimulation, and 10 days after the last stimulation
(Table 1). As shown, all scales showed a statistically
significant improvement at the end of the treatment
(after six stimulations), and this improvement was
maintained after 10 days after the completion of treat-
ment; the only value that was not significant at the 10-day
follow-up is that of the Tinetti scale.
Spatiotemporal variables results
Figure 2 presents the results of the percentage of
improvement for each presented variable. Differences
were found between pre-AMPS intervention and all
other postintervention trials for stride (Fig. 2a), step
length (Fig. 2b), mean velocity (Fig. 2c), swing velocity
(Fig. 2d), and cadence (Fig. 2e).
Differences were found between the control group and
all intervention trials for step length, step width, stride
length, swing phase, stance phase, double support, mean
velocity, stride velocity, and swing velocity. The only
difference between pre-AMPS and the control group was
found in cadence; for the other postintervention trials and
the control group, no differences were found. Table 2
shows these data.
Discussion
In this study, we evaluated from a longitudinal perspec-
tive the effects of an innovative treatment for the AMPS
of the afferent pathways of the foot in patients with PD.
When the clinical scales were compared, the results
showed that PD patients had a decrease in the severity of
symptoms, an increase in functionality and independence
to perform their day-to-day activities, and a reduced risk
of falling. Moreover, participants with PD showed
improvement in gait parameters after intervention with
AMPS. PD patients showed significant improvements in
the spatiotemporal parameters of gait. Interestingly, after
the first AMPS, the cadence of PD group patients
reached normative values. Because no differences were
recorded in values after six AMPS treatments and 10 days
after the last treatment, it appears that AMPS treatment
reduces gait impairment (according to all parameters and
spatiotemporal gait parameters) in PD patients, with
positive effects lasting for at least 10 days after the
treatment cycle.
Seiss et al. (2003) found evidence that muscle spindle
sensitivity is normal in individuals with PD and con-
cluded that proprioceptive impairment is in the central
processing of the sensory information. Pratorius et al.
(2003) carried out a study investigating the sensitivity of
the sole of the foot in individuals with PD. They found
that PD patients have significantly higher thresholds of
sensitivity, and thus, PD patients require an amplified
stimulus to overcome the increased threshold. They also
found a relationship between severity and threshold, in
which more severely affected patients show higher sen-
sitivity thresholds (Pratorius et al., 2003). In accordance
with this, Dietz and Colombo (1998) found that indivi-
duals with PD show reduced load sensitivity and,
therefore, an increased threshold in the lower leg
receptors, which may also contribute toward the move-
ment deficits found in PD. If the deficit lies solely in the
sensory receptors themselves, then an increase in sti-
mulus intensity should be able to overcome the defective
sensory receptors that may be responsible for the pro-
prioceptive deficit, as suggested in previous research
(Tsuchida et al., 2013; Raggi et al., 2014).
On the basis of these findings, we hypothesize that
AMPS elicited stretch reflexes in the muscle throughout
the leg. The AMPS can induce a response from the
Table 1 Clinical scales’ comparisons
Intervention UPDRS III PDQ39 TUG FAC 10MWT Tinetti
Pre 27.44 ±6.42 51.87 ±31.320 16.12 ±5.51 3.75 ±1.035 0.4925 ±0.04 11.42 ±1.90
Post 6 AMPS 19.22 ±3.66* 39.5 ±23.25* 12.75 ±1.75* 4.5 ±0.75* 0.53 ±0.06* 14.71 ±1.60*
Post 10 days 23.66 ±4.03** 42.12 ±22.29** 14.37 ±2.13** 4.25 ±0.88** 0.51 ±0.05 13 ±1.82**
AMPS, automated mechanical peripheral stimulation; FAC, Functional Ambulation Classification; 10MWT, 10 Meters Walk Test; PDQ39, Parkinson’s Disease
Questionnaire; Tinetti, Tinetti Assessment Tool; TUG, Timed Up and Go; UPDRS III, Unified Parkinson’s Disease Rating Scale III.
*P≤0.05, pre versus post 6 AMPS.
**P≤0.05, pre versus post 10 days.
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proprioceptors, which in turn can affect the gait of an
individual. This is reasonable to expect because various
types of sensory receptors work together to provide
accurate feedback to the central nervous system during
locomotion. Thus, mechanical facilitation of the plantar
surface may be able to increase the sensory stimulation
Fig. 2
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received to overcome the proprioceptive deficits that
impair gait in individuals with PD.
Current therapeutic options for treating these gait dis-
turbances and reducing patients' risk of fall in PD are
quite limited. Despite advances in pharmacologic ther-
apy and surgical procedures, impairments in gait and
balance remain common in PD patients (Grimbergen
et al., 2004). The development of an add-on therapy and
rehabilitation-like approaches is important for the man-
agement and the well-being of patients living with PD.
The results of this study provide new insights into using
the AMPS as an effective therapy for the well-being of
PD patients through improvement in gait.
In any case, the current study has some limitations, pri-
marily because of the limited strength of the statistical
findings because of the reduced number of participants
studied. Despite this limitation, the outcomes show that
this innovative treatment can provide patients living with
PD with a noninvasive add-on therapy to reduce gait and
balance impairments. Additional studies are advised to
further document and confirm the positive, encouraging
effects of AMPS treatment in PD. Parameters of gait
kinetics should also be included in a future study because
they have not been analyzed in this study.
Conclusion
The study outcomes indicate that AMPS treatment
applied to PD patients improves gait, mobility, and
quality of life. These findings indicate that AMPS may
promote a more stable walking pattern in patients with
PD and that long-term repetition of AMPS treatment is
apparently able to restore the rhythmicity of gait and
reduce the risk of falls. In most cases of patients living
with PD, the goal of treatments is ‘maintenance’ care;
this study shows that rehabilitation approaches can
indeed reduce gait and balance impairments because of
this neurodegenerative condition, improving the
patient’s quality of life. This study contributes toward a
growing body of evidence that AMPS may be a useful
approach to treat neurodegenerative diseases such as PD.
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Swing phase (%) 36.08 ±4.79a 37.11 ± 3.98b 37.46 ± 4.51c 37.76 ±3.81d 37.13 ±5.35e 39.45 ±1.76a,b,c,d,e
Stance phase (%) 63.91 ±4.79a 62.88 ± 3.98b 62.53 ± 4.51c 62.23 ±3.81d 62.86 ±5.35e 60.55 ±1.76a,b,c,d,e
Double support (%) 13.5 ±4.54a 12.88 ± 3.46b 12.49 ± 4.39c 12.92 ±5.05d 13.11 ±5.13e 10.83 ±1.76a,b,c,d,e
Mean velocity (m/s) 0.67 ±0.3a 0.8 ± 0.3b 0.77 ± 0.29c 0.76 ±0.31d 0.8 ±0.29e 1.04 ±0.15a,b,c,d,e
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Cadence (steps/min) 100.66 ±12.47a 109.05 ± 14.24 111.07 ± 14.7 116.23 ±33.84 105.66 ±17.36 110.73 ±5.34a
AMPS, automated mechanical peripheral stimulation; CG, control group; PD, Parkinson’s disease.
aDifferences between Pre and CG.
bDifferences between Post and CG.
cDifferences between 6 AMPS and CG.
dDifferences between 48 h and CG.
eDifferences between 10 days and CG.
244 International Journal of Rehabilitation Research 2015, Vol 38 No 3
Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved.
Novak P, Novak V (2006). Effect of step-synchronized vibration stimulation of
soles on gait in Parkinson’s disease: a pilot study. J Neuroeng Rehabil 3:9.
Nutt JG, Wooten GF (2005). Clinical practice. Diagnosis and initial management
of Parkinson’s disease. N Engl J Med 353:1021–1027.
Perry SD, Radtke A, McIlroyWE, Fernie GR, Maki BE (2008). Efficacy and effectiveness
of a balance-enhancing insole. J Gerontol A Biol Sci Med Sci 63:595–602.
Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995). The development and
validation of a short measure of functioning and well being for individuals with
Parkinson’s disease. Qual Life Res 4:241–248.
Podsiadlo D, Richardson S (1991). The timed “up& go”: A test of basic functional
mobility for frail elderly persons. JAGS 39:142–148.
Pratorius B, Kimmeskamp S, Milani TL (2003). The sensitivity of the sole of the
foot in patients with Morbus Parkinson. Neurosci Lett 346:173–176.
Priplata AA, Niemi JB, Harry JD, Lipsitz LA, Collins JJ (2003). Vibrating insoles and
balance control in elderly people. Lancet 362:1123–1124.
Raggi A, Covelli V, Pagani M, Meucci P, Martinuzzi A, Buffoni M, et al. (2014).
Sociodemographic features and diagnoses as predictors of severe disability
in a sample of adults applying for disability certification. IJRR 37:
180–186.
Seiss E, Praamstra P, Hesse CW, Rickards H (2003). Proprioceptive sensory
function in Parkinson’s disease and Huntington’s disease: evidence from
proprioception-related EEG potentials. Exp Brain Res 148:308–319.
Tinetti ME, Williams TF, Mayewski R (1986). Fall Risk Index for elderly patients
based on number of chronic disabilities. Am J Med 80:429–434.
Tsuchida W, Nakagawa K, Kawahara Y, Yuge L (2013). Influence of dual-task
performance on muscle and brain activity. IJRR 36:127–133.
Long-term effects of AMPS in Parkinson’s Stocchi et al. 245
Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved.
